PPMD Recommends Marathon Convene Broad Array of Duchenne Stakeholders to Discuss Re-evaluation of Deflazacort Pricing

In light of the pause in commercialization of EMFLAZA ™ (deflazacort) by Marathon Pharmaceuticals earlier this week, PPMD recommends that Marathon seek input from a broad array of stakeholders including Duchenne clinicians, health insurance plans, pharmacy benefit managers, and Duchenne advocacy groups.
Source: Parent Project Muscular Dystrophy - Category: Neurology Source Type: news